Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...
Tag - BioLineRx
Copyright © 2024 BioTuesday Publishing Corporation - Privacy Policy